Develops and commercializes novel therapeutics and consumer health products for various medical conditions.
Aytu BioPharma, Inc., a specialized pharmaceutical company headquartered in Englewood, Colorado, is dedicated to advancing and commercializing innovative therapeutics and consumer healthcare products across the United States and globally. The company's portfolio includes Adzenys XR-ODT and Cotempla XR-ODT, both indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients aged six years and older. Additionally, Aytu BioPharma offers Karbinal ER, an oral suspension of carbinoxamine used to alleviate symptoms of seasonal and perennial allergies.
In the realm of consumer healthcare, Aytu BioPharma provides Poly-Vi-Flor and Tri-Vi-Flor prescription supplements tailored for infants and children to address fluoride deficiency. These products underscore the company's commitment to enhancing pediatric health through specialized nutritional supplementation. Originally known as Aytu BioScience, Inc., the company rebranded as Aytu BioPharma, Inc. in March 2021 to better reflect its focus and expanded scope in the pharmaceutical industry.
Founded in 2015, Aytu BioPharma leverages its expertise in pharmaceutical development to deliverr high-quality, effective treatments that meet the needs of patients and healthcare providers alike. With a robust pipeline and strategic initiatives aimed at growth and innovation, Aytu BioPharma continues to play a pivotal role in advancing healthcare solutions that improve patient outcomes worldwide.